Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
May 8, 2025
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being here for our business update and earnings call for the first quarter of 2025. On the line with me today is my colleague Lisa Delfini, who serves as Trevi's Chief Financial Officer, along with Dr. James Cassella, our Chief Development Officer, and Farrell Simon, our Chief Commercial Officer. Lisa and I have some remarks to share regarding the business and financial results, and after that, the team would be glad to take whatever questions you might have. Trevi carried the robust momentum from 2024 straight into the first quarter of 2025, thanks to the positive data readout from the Phase 2a RIVER Trial involving RCC patients, plus completion of enrollment for the Phase 2b CORAL trial in IPF chronic cough patients. I'll go into more detail on both programs shortly, but it goes without saying that these past few months have been quite exciting for us. Back in March, we shared data from our Phase 2a RIVER trial in patients suffering from refractory chronic cough, or RCC, which encompasses those with unexplained chronic cough. RCC is a debilitating condition impacting roughly 2 to 3 million patients in the US, and there are no approved therapies for it in the US. Notably, numerous drugs have been studied for this condition and failed — all mainly peripherally acting agents — with just one drug, GSK's camlipixant, still in late-stage development. Our hypothesis going into the RIVER study was that our central and peripheral mechanism might alter outcomes for RCC patients by delivering a bigger effect, while also working across a wider range of cough counts than other peripheral-only therapies currently in development. RCC is thought to stem from cough hypersensitivity at the brain level, which is why we believe the central activity of our mechanism matters and sets it apart; in the Phase 2a RIVER study, Haduvio hit the primary endpoint with a statistically significant reduction in 24-hour objective cough frequency, achieving a P value of less than 0.0001. There was a 57% placebo adjusted reduction in cough from baseline and, importantly, the same strong effect appeared across a broad range of cough counts, including patients with moderate and severe cough frequencies. In our top line announcement, we also presented two patient reported secondary endpoints — cough severity and cough frequency — that were highly statistically significant and supported the primary endpoint from the objective cough monitor. Since reporting those data, we've received the full data set and can confirm that every prespecified secondary endpoint in the study was statistically significant at the end of treatment. The RIVER data mattered not only for potential therapeutic value to patients but scientifically too. Haduvio is the first mechanism to work in both patients with RCC and in IPF patients with chronic cough; we see this as evidence of the importance of the central mechanism underlying neurogenic chronic cough conditions, and it lays the groundwork for not having to do the enrichment strategies others have employed to show statistical significance in RCC. Moving on to our main program for IPF patients dealing with chronic cough. In Q1, we wrapped up enrollment for the Phase 2b CORAL study focused on treating this condition. Then in April, the final participant finished their final visit. About 160 patients signed up for this trial, spanning 10 nations and 60 locations. Right now, the team is scrubbing the data and getting ready for database lock, which keeps us on schedule for top line results during this quarter. We're eager to receive results from this dose ranging study and push the development effort ahead in both chronic cough indications—IPF and RCC. When it comes to the FDA, plenty is happening there that concerns every one of us. I'd like to share what we went through lately, since I believe it matters for everyone to keep an eye on how this key regulatory agency is doing; we sought advice via a Type C request, with written answers only, regarding a technical issue in our program. Happily, the FDA hit their target date this month and gave us replies containing unambiguous direction; we know FDA personnel are swamped and value their work helping companies continue their development efforts. Feedback from the FDA is essential throughout development, and we're hopeful that fresh leadership will make this part of the agency's mission a priority; so, in closing, everyone's attention is on the IPF chronic cough data. This group of patients has seen minimal therapeutic innovation across the last 10 years, particularly regarding enhancements to their everyday experience of living with IPF. On another note, we're getting ready to be very visible at ATS in San Francisco in just a couple weeks. Several of my colleagues and I will be present, so if you're going, just tell me. For investors and analysts, we're putting on a KOL panel that includes IPF specialists plus an RCC physician, and turnout is already strong. We intend to reveal fresh findings from the complete RCC data set, which we'll post online afterward too. Additionally, we'll take part in an investor dinner and will be busy going to sessions throughout the conference. Sadly, our RCC data arrived too late for inclusion in this conference's late breaker deadlines; nonetheless, we're planning to send in abstracts covering analyses from both the RIVER and CORAL trials for the European Respiratory Society gathering in September. At this point I'll hand things over to Lisa for our financial results. After that, we'll take any questions you might have.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon to all of you. You'll find the complete financial results for the 3 months that ended March 31, 2025 in the press release we issued before this call, as well as in our 10-Q, which we filed with the SEC today after the market closed. During the first quarter of 2025, our net loss came to $10.4 million, versus a net loss of $10.9 million in the same quarter of 2024. R&D expenses totaled $7.8 million in the first quarter of 2025, compared with $8.8 million in the same quarter of 2024. That decrease stemmed mainly from lower costs tied to our Human Abuse Potential study, which was actively enrolling during the first quarter of 2024; higher personnel related expenses from a larger headcount partially offset this. G&A expenses rose to $3.7 million in the first quarter of 2025, up from $3.1 million in the same period of 2024, largely because of greater personnel related expenses. As of March 31, 2025, cash and investments came to $103.3 million, which provides runway into the fourth quarter of 2026. We intend to use that cash to finish our ongoing Phase 2b CORAL trial of Haduvio for chronic cough in patients with IPF; and on the basis of those data, we will decide the development path forward for our programs along with the related financing needs. Across the first four months of this year, we had a total of 7.9 million common stock warrant exercises. At present, roughly 1.9 million common stock warrants remain outstanding. Our current fully diluted shares outstanding stand at approximately 137 million, which includes 101.7 million shares outstanding. Those 1.9 million common stock warrants, about 23.2 million prefunded warrants and approximately 10 million stock options. That wraps up our prepared remarks. I'll now hand the call back to the operator for Q&A.
Faisal Khurshid
analystHi, thanks for answering my question. I just wanted to ask if you could remind us, for the CORAL readout, what you'd consider an encouraging or positive result on both the efficacy side and the safety side. And does that mean hitting the statistical bar? Is there anything beyond that too? I also have a follow-up.
Jennifer Good
executiveThank you, Faisal, for that question. For this trial, I think, since so little exists, this condition is so difficult, and these patients truly have nothing; we powered this study quickly so we could move forward. And I think, unlike RCC, where other programs existed, we had to think about things as far as advancing; for this program, a statistically significant positive trial means we will keep advancing in development. So that's the bar for us for success. On the safety side, I think, just continuing, no kind of unusual adverse events that we didn't see, no safety signals which we would already know at this point. So, I'm comfortable we kind of crossed that bar. We've also shared before that our discontinuations are less than 10%. So, I think from a level perspective, I think, we'll look at, obviously, kind of the AE profile and things, but we've seen a lot of that so far, and there's nothing jumping out as unusual here. So really, I think it's just a matter of having positive data here and what it looks like.
Faisal Khurshid
analystUnderstood. That's helpful. And could you refresh our memory on what the upcoming catalyst for the company might be, roughly over the next year or so, as we emerge from the CORAL readout?
Jennifer Good
executiveFaisal, I'm going to defer that a bit further out, since after we receive the IPF data, I believe we'll be better positioned to map out the catalyst path ahead. What I mean is, we've discussed — we need to go to the FDA and meet with them based on the IPF results, assuming those results are positive. And Jim and Farrell are doing some work around preparing to run a basket trial in interstitial lung disease, which we can discuss further. And I think after we get the IPF data and we're clear on the path forward, we'll map out a solid catalyst track coming out of our IPF data.
Faisal Khurshid
analystThat's excellent. I appreciate your willingness to answer our questions, and I'm eager to see you in San Francisco.
Jennifer Good
executiveWonderful. Thank you, Faisal.
Annabel Samimy
analystHello, and thank you for taking my question. I wanted to ask a bit more about the discontinuation rate that you brought up. You said it came in under 10%. Could you remind us of the powering assumption? Also, did that powering rest on discontinuations overall, or only on those tied to adverse events? Then, as a follow-up, now that we have positive data in CORAL and RIVER along with positive SSRE, what do you still see as the largest hurdle or source of uncertainty as you head into this ILD study — apologies, I mean the IPF study.
Jennifer Good
executiveI'll have Jim address the statistics question.
James Cassella
executiveRight, so the assumption we built in for that trial was a 30% rate of discontinuation, and as it turned out, the actual figure was far below that.
Jennifer Good
executiveYes, and Annabel, regarding what you mentioned, the real question is how much uncertainty remains. Honestly, none of us ever truly stops being anxious about these studies. I believe we did get solid Phase 2a data. RCC clearly provided supporting evidence. The SSRE was, I'd say, reassuring. Still, this is a challenging study. These are difficult patients. It spans 60 different sites in 10 countries. Jim, I think, never ceases worrying about every single element of this study, so it will be a relief when the results are revealed, no doubt. And it's such a critical indication that I believe all of us carry that weight. But no, we're optimistic as we approach the readout.
Annabel Samimy
analystOkay. Great. Thank you.
Jennifer Good
executiveYeah, thank you.
Leland Gershell
analystHi there, good afternoon. Appreciate you taking our questions. I'll limit myself to just one. I'm curious, Jennifer — it's been roughly a bit more than 12 months since data came out from the PACIFY study, which looked at low dose-controlled release morphine for IPF chronic cough, and as I recall it showed a rather modest 20% gain in cough counts. I'm just wondering, now that Simon has departed, whether you've gotten any feedback or done any reflecting based on what the physician community has said about that data, and whether that substance might have any potential role for IPF chronic cough? Thanks.
Jennifer Good
executiveYeah, no, that's a great question, Leland. Okay, so PACIFY was a single-site study that took place in the UK, and it was run by Dr. Phil Molyneaux. He's also the lead investigator on our IPF trial. He's a highly respected individual. What the study essentially showed was a 40% drug effect from a MU agonist, but there was a zero-placebo effect, which was likely artificial. I think that's kind of a result of it being a single site with his patients. As you're aware, in our data sets we've seen a drug effect somewhere in the range of 67% to 74%. So that's a larger effect — and I believe the community shares our view, which is that the CAPA side of our mechanism is important here. Clearly, it's almost doubling the effect size. Morphine, in my view, brings along a separate set of problems. Keeping the dose at a low level is necessary; you run into respiratory depression; there's also the risk of addiction. Because of that, I've seen this concern brought up by people during different panel discussions. For those physicians, I believe, having any way to shift patients onto a medication that isn't classified as Schedule 2 and lacks the respiratory depression concerns would represent a superior option. That it delivers substantially stronger efficacy is simply an extra benefit; so, although morphine was intriguing, it does confirm the mechanism. Our drugs, I'd say, keep showing better results. Jim, you're a CNS guy. Anything you would want to add to that?
James Cassella
executiveNo, I'd say that covers it. I believe it perhaps demonstrates — possibly the shortcoming of that specific medication in this area; and I think mention of a 0% placebo response inevitably prompts doubts regarding perhaps the study design or the fact that it was conducted at a single center.
Jennifer Good
executiveYeah, fair enough. Thanks for the question, Leland.
Analyst
analystHello, and good afternoon. John here, filling in for Serge today. We appreciate you answering our question. About that respiratory physiology study — I'm wondering whether it remains on schedule to wrap up during the second half of this year. Also, from what I understand, your team has been considering adding a 108-milligram dose into that study. I'd like to know if anything has changed since March. Thank you.
James Cassella
executiveHello, Jim speaking. I believe we remain on schedule for that timeline. The study continues to move forward, and that timeline should hold fine.
Jennifer Good
executiveYes, and John, we are handling our clinical doses, and we feel at ease. That will address the question. All right. Thanks. And on that point, just a reminder for everybody, we truly need this data when we next speak with the FDA regarding the program going forward; so that is sort of what we are working toward here, and we are comfortable that we will manage to do so. Please proceed, Ariel.
Deepa Njama
analystHello, and thank you for allowing me to ask. Could you share any further details about which data points we might see at ATS based on the extra RIVER data that's coming in?
Jennifer Good
executiveYes, glad to. Hello, Deepa. The presentation is still being put together, but my sense is we'll cover some of what the sell side and investors have been asking us, which centers a bit on the timeframe. So, more analysis regarding when AEs happened, the timing of them, the discontinuations, and what caused those. We'll present a handful of patient vignettes drawn from the trial — how they presented, the duration of their cough, and what took place over the course of the trial. We'll also present data on the Leicester cough questionnaire, a QOL instrument, and then, if we're able to get it all together, we'll present the treatment period effect from the crossover. Work is underway on that; we now understand there was no treatment period effect, yet we do receive questions about what the effect size appeared to be within each treatment period. That's what we currently intend. Jim and I don't wish to consume too much time; we'll likely speak for 15, 20 minutes. But we have a fantastic panel — thank you, Leland, who will Moderate alongside Dr. Toby Mayer, likely the foremost global expert in ILD, Nazia Chowdhury, who is in fact an investigator on our IPF trial. She's a wonderful person too; and then Dr. Dispeningidis <<inaudible>>, whom many of you have heard present, is more or less the top authority in the US on RCC. So, we'll have a good open conversation with them and essentially open up the room, with Leland moderating throughout; that's what's planned for that time, and the response we've received has been very positive. So, the room ought to be nicely full for it.
Deepa Njama
analystThanks a lot. That's really useful, and I can't wait to meet up with you at SS.
Jennifer Good
executiveAbsolutely, thank you — same here.
Mayank Mamtani
analystGood afternoon, everyone. Appreciate you taking my question, and congratulations on the progress with the RIVER data follow-up. You're looking to determine, for the upcoming steps, some further work on dose exploration. Jennifer, could you perhaps share your most current thinking on that? Then, I suppose, a connected question regarding the ILD study. Have you designed the protocol — the crossover compared with a parallel arm design — and what would that look like? Also, is there anything from the IPF chronic cough data set that could inform how we think about the ILD study's probability of success?
Jennifer Good
executiveYes. I'll handle the first portion. Jim, perhaps you could handle the second portion and determine whether to bring Farrell in. Regarding dose exploration, Mayank, the upcoming step for us is that we're awaiting that IPF data. It's a crucial data set. It's a parallel arm. We do believe synergies exist between RCC and IPF. So Jim's team has been occupied with some planning and sort of synopses and things of that nature. But we're going to hold off and see the IPF data set, then determine the path forward sort of for both programs going ahead. I think. Jim, Farrell, I'll hand it over to you folks to discuss ILDs and sort of where things stand in your thinking on that.
James Cassella
executiveLet me give a quick overview of our current thinking on the trial design. Farrell will cover some of the remaining commercial and patient-related aspects. The important thing, though, is that these kinds of crossover studies have generated a great deal of learning, and we will certainly make use of that crossover design. We intend to follow the same path established by the IPF work we have already completed, so you should expect us to conduct a trial of a similar type. The central issue here, in my view, is not the trial design, the endpoints, or matters of that sort. What really matters is the character of the population. Farrell and I have been examining this from several angles and speaking with KOLs, and since Farrell has been approaching it from the commercial perspective, I will let him weigh in on that part as well.
Farrell Simon
executiveOkay, appreciate the question, Mayank. If we turn to the non-IPF ILD group, we're drawing one line differently from how the anti-fibrotics do it. Those drugs primarily approach this through progressive pulmonary fibrosis, which means a progressive phenotype has to be present before any change in FEC can be observed over time. With a chronic cough treatment in this area, things work another way. Two measures are genuinely required. Jim mentioned this — we need someone who has ILD with fibrosis, plus someone with chronic cough, and the intersection between those two groups. That widens the population. We're simply doing a better job of defining it, and we expect to share additional detail on the data call for oral.
Jennifer Good
executiveYes, and Mayank, let me just jump in there. IPF is clearly a major catalyst for that too. So if the IPF trial comes back positive, with any luck we can provide a bit more detail on that front.
Mayank Mamtani
analystYeah, that's really useful. And a quick follow-up regarding what you said about the recent FDA Type C meeting. Could you share what that meeting covered? And also, of course, whether you have plans for the next round of FDA engagement — I think that would be the end of Phase 2 meeting for IPF chronicles. Thanks for answering that.
Jennifer Good
executiveSure; regarding the technical side, Mayank, it's simply about validate — the entire validation surrounding the primary endpoints. The same problem everyone is aware of regarding cost counting, making clear what we have to do. So luckily, the FDA has considered that and I think it's clear. Jim, I'll let you weigh in on your thoughts going forward with FDA.
James Cassella
executiveSure. So, it's really encouraging, I'd say. Once again, this was a pretty targeted question. The FDA got back to us on schedule, and they provided suitable responses or clarifications for us. So for us, that's a really positive signal. Our plan is to hold the right meetings. We anticipate that the FDA will stay engaged with us, since we'll need to approach them for follow-up on the RCC program as well as the IPF program. So, fingers crossed that everything stays steady there for all of us.
Jennifer Good
executiveThanks, Mayank.
Kaveri Pohlman
analystYes. Good evening. I appreciate the updates, and thank you for answering my question. What I'd like to hear is your perspective regarding safety results and how patients fare over the long run. As it stands, the plan appears to leave out long-term patient safety monitoring protocols mandated by the FDA, and that holds true even for the Phase 3 trial. Has the agency given you any response regarding this? Might the safety data accumulated across decades for the already-existing formulation be accepted as a suitable substitute?
James Cassella
executiveHello. Jim here; we do, in fact, possess fairly solid understanding of what will be needed concerning long-term safety. Not only has the FDA communicated to other parties working in the RCC space that, from their standpoint, 52 weeks represents a key time point. Thus, when we file the NDA, our plan had been to have 52 weeks of safety data available. Within the Phase 3 program, there are methods for accomplishing this through distinct long-term extension trials. Therefore, we intend to ensure that 52 weeks of safety are included; and naturally, within that trial, we can additionally examine ongoing impacts on cough. So I believe this is part of our plans, and we will be pursuing it.
Kaveri Pohlman
analystAll right, that's quite useful. And perhaps as we move forward, before launching large Phase 3 studies — what's your present view regarding possible partnerships inside the US or outside it? Thank you for taking my question.
Jennifer Good
executiveYes. What I'd say is, strategic discussions are something we're engaged in constantly. I'd put it this way — we believe we're ready and getting set to manage this on our own in the US, unless someone simply comes in and acquires the whole company. Farrell is continuously in talks with a range of possible partners for commercialization across Europe and Japan. And I'd say that, based on the data and on timing, that option is definitely available.
Kaveri Pohlman
analystGot it. Thank you.
Jennifer Good
executiveYeah. Thank you.
Analyst
analystHello there, and good afternoon. Anthony here, covering for Ryan. The question we had was whether you've noticed any patterns within the RIVER study regarding baseline patient characteristics — things like prior therapies or the original disease etiology?
Jennifer Good
executiveThat's likely premature to be asking, so I'll pass that over to you.
James Cassella
executiveWe're taking a hard look at every piece of the data. Right now, I'm not able to say that I've got a solution for that. It's obviously among the analyses that we're going to pull together and get ready to present at some meeting down the road.
Jennifer Good
executiveI mean, this medication, as you likely recall, Anthony, was effective for absolutely every single person to a significant degree. So it's tough to spot patterns of perhaps where it failed. But they're going, more or less, one patient at a time, attempting to figure out what we're able to observe in this situation.
Analyst
analystOK, thanks a lot.
Jennifer Good
executiveYes, thanks.
Jennifer Good
executiveThanks — we’re eager for the Phase 2b CORAL trial readout later this quarter, and we’re glad each of you could be on today’s call. Once the call wraps up, we’ll be around to address any follow-up questions you might have. We appreciate your participation.
Operator
operatorThat brings us to the end of this conference call. We appreciate your joining today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.